NFKB1 and familial pancreatic carcinoma: Drugs that increase O2●− (Methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate [CDDO-Me], dicumarol) have been shown to downregulate important growth regulators in pancreatic cancer including hTERT, p-AKT, p-MTOR, NF-κB, c-myc, SP1, and telomerases, and to induce apoptosis [93,94].